Autopsy report · NCT02840162

Pre-Prostatectomy Celecoxib or Placebo

“Drug safety concerns”

The sponsor’s own words in the registry.

Life of this trial

• Registered 15 years 2 months after it had already started.
• Ran for about 10 years before it stopped.
• 34 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

OHSU Knight Cancer Institute

Sponsor type

University, hospital or other

Conditions

Adenocarcinoma of the Prostate; Prostate Cancer

Interventions

Celecoxib; Placebo

Participants

34

Sites

2

Countries

United States

Trials that died the same way

• Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset
  “Lack of efficacy of the drug; no safety concern” (72% match in meaning)
• VA Remote and Equitable Access to COVID-19 Healthcare Delivery (VA-REACH TRIAL)
  “concerns related to study drug” (69% match in meaning)
• tailOred dRug repurposIng of dEcitabine in KRAS-dependeNt refracTory pAncreaTic cancEr
  “Unexpected toxicity events were documented during interim safety evaluations of the investigational drug.” (64% match in meaning)
• A Phase I Trial of a LTK63 Adjuvated Tuberculosis Nasal Subunit Vaccine (Ag85B-ESAT6)
  “Safety Issues” (60% match in meaning)
• Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors
  “Not related to safety concerns or lack of efficacy” (60% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.